Questions around this news
What did LIXTE acquire from Liora Technologies?
The release says LIXTE acquired Liora Technologies, which is becoming a wholly owned subsidiary. The deal includes Liora’s proprietary LiGHT System, a proton therapy system intended for treating tumors. The release describes Liora as a company developing proton therapy systems for tumors in different types of cancer.
What is the LiGHT System designed to do?
LiGHT stands for Linac for Image Guided Hadron Therapy. The release describes it as an adaptable system that delivers a proton beam and says it can provide very high dose rates to deep-seated tumors. It also reports claims that the system could reduce installation costs and treatment sessions, and help centers serve more patients.
How does proton therapy treat tumors?
Proton therapy uses beams of positively charged particles, called protons, to deliver radiation to a tumor. The beam can be adjusted to concentrate its radiation at a selected depth, which may limit exposure to some surrounding tissue. Treatment planning and delivery depend on the tumor’s location and the patient’s clinical circumstances.
What is a PP2A inhibitor?
PP2A is a protein phosphatase, a type of enzyme that helps regulate cell activity by removing phosphate groups from proteins. A PP2A inhibitor reduces or blocks that enzyme’s activity. Researchers study such compounds for their potential effects on cancer cells, but their effects and clinical use depend on the specific drug and evidence from testing.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move.
“The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology at CERN. “In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. “
To view the full article, visit https://ibn.fm/W6gD5
About LIXTE Biotechnology Holdings Inc.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
At a glance
- Company
- LIXTE Biotechnology Holdings
- Ticker
- NASDAQ: LIXT
- Announcement
- Acquisition
People
- Professor Steve MyersFormer Director of Accelerators and Technology at CERN
Products and programs
Earlier from LIXTE Biotechnology Holdings Inc.
- LIXTE Biotechnology (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
- LIXTE Biotechnology (NASDAQ: LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment
- LIXTE Biotechnology (NASDAQ: LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment
- LIXTE Biotechnology Holdings (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
